Clinical analysis of carcinomatous meningitis in 63 cases

( views:113, downloads:0 )
Author:
YI Shuai(Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China)
ZHAO Lu-jun(Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China)
PANG Qing-song(Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China)
YUAN Zhi-yong(Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China)
CAO Ling(Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China)
WANG Ping(Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, China)
Journal Title:
CHINESE JOURNAL OF RADIATION ONCOLOGY
Issue:
Volume 20, Issue 01, 2011
DOI:
10.3760/cma.j.issn.1004-4221.2010.06.002
Key Word:
Meningeal neoplasms/radiotherapy;Meningeal neoplasms/chemotherapy;Prognosis

Abstract: Objective To analyze the clinical characteristics and the prognostic factors of carcinomatous meningitis(CM). Methods 63 patients with CM treated in Tianjin Medical University Cancer Institute and Hospital from 1998 to 2008 were reviewed retrospectively. The correlations between clinical characteristics, treatment modalities and the prognosis of CM were analyzed. The common primary site was lung cancer(65%)and breast cancer(13%). All the patients were underwent MRI scan and 29 of the patients received lumbar puncture. Fifty-one patients received whole brain radiotherapy, systemic and/or intrathecal chemotherapy. The other 12 patients only received supportive care. Kaplan-Meier method and Log-rank test were used for survival analysis. Results All patients died by the end of follow-up. The follow-up rate was 95%. The number of patients who undergone 1-,2 years follow-up were 59 and 56. The median survival time was 2. 2 months(range :0. 1 -24. 4 months)for the entire group. The clinical stage and the control status of the primary disease were strongly correlated with survival(x2 = 6. 68, P = 0. 036)and(x2 = 7.04, P = 0. 008). The median survival time was 3.0 months(range: 1.0 - 24. 4 months)in patients who received ≥30 Gy whole brain irradiation, while only 1.8 months(range:0. 1-14. 2 months)in those who did not receive radiotherapy(x2 =5.54,P =0. 019). The median survival time of radiotherapy ± chemotherapy group, chemotherapy only group and supportive treatment only group were 3.0 months (range :0. 5 - 24. 4 months), 2. 2 months(range :0. 3 - 14. 2 months)and 1. 2 months(range :0. 1 - 4.5 months), respectively(x2 = 9. 32, P = 0. 009). Conclusions The prognosis of CM is very poor. The clinical stage before the diagnosis of CM and the control status of primary disease and were significantly correlated with survival. Sufficient whole brain irradiation dose may prolong survival and worth further study in a large sample study.

  • [1]Hammerer V,Pauli G,Quoix E.Retrospective study of a series of 26 carcinomatous meningitis secondary to lung cancer.Bull Cancer,2005,92:989-994.
  • [2]Demopoulos A.Leptomeningeal metastases.Curr Neurol Neurosci Rep,2004,4:196-204.
  • [3]Shapiro WR,Johanson CE,Boogerd W.Treatment modalities for leptomeningeal metastases.Semin Oncol,2009,36:46-54.
  • [4]Hammerer V.Diagnosis and treatment of carcinomatous meningitis in lung cancer.Rev Mal Respir,2007,24:6S222-225.
  • [5]Taillibert S,Laigle-Donadey F,Chodkiewicz C,et al.Leptomeningeal metastases from solid malignancy:a review.J Neurooncol,2005,75:85-99.
  • [6]Doctor AM,Sharma S,Maheshwari M.Meningeal carcinomatosis from pulmonary adenocarcinoma.Indian J Cancer,2008,45:74-75.
  • [7]Chowdhary S,Chamberlain M.Leptomeningeal metastases:current concepts and management guidelines.J Natl Compr Canc Netw,2005,3:693-703.
  • [8]Pavlidis N.The diagnostic and therapeutic management of leptomeningeal carcinomatosis.Ann Oncol,2004,15(Suppl 4):285-291.
  • [9]Sudo J,Honmura Y,Kurimoto F,et al.Meningeal carcinomatosis in patients with lung cancer.Nihon Kokyuki Gakkai Zasshi,2006,44:795-799.
  • [10]Boogerd W,Hart AA,van der Sande JJ,et al.Meningeal carcinomatosis in breast cancer.Prognostic factors and influence of treatment.Cancer,1991,67:1685-1695.
  • [11]Feyer P,Sautter-Bihl ML,Budach W,et al.DECRO Practical Guidelines for palliative radiotherapy of breast cancer patients:brain metastases and leptomeningeal carcinomatosis.Strahlenther Onkol,2010,186:63-69.
  • [12]Berg SL,Chamberlain MC.Current treatment of leptomeningeal metastases:systemic chemotherapy,intrathecal chemotherapy and symptom management.Cancer Treat Res,2005,125:121-146.
  • [13]Yoshida S,Morii K.Intrathecal chemotherapy for patients with meningeal carcinomatosis.Surg Neurol,2005,63:52-55.
  • [14]Clarke JL,Pao W,Wu N,et al.High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal gowth factor receptor mutant lung cancer.J Neurooncol,2010,99:283-286.
  • [15]Laufman LR,Forsthoefel KF.Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.Clin Breast Cancer,2001,2:235.
  • [16]Grossman SA,Krabak MJ.Leptomeningeal carcinomatosis.Cancer Treat Rev,1999,25:103-119.
  • [17]Bruno MK,Raizer J.Leptomeningeal metastases from solid tumors (meningeal carcinomatosis).Cancer Treat Res,2005,125:31-52.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn